Exhibiting at Hi Japan 2024

Zhejiang Medicine Co., Ltd. is a large-scale joint-stock pharmaceutical company established in May 1997. The company was listed on the Shanghai Stock Exchange in October 1999. With a registered capital of 960 million yuan and total assets of 10 billion yuan, Zhejiang Medicine has developed into a technologically advanced, large-scale, and globally influential pharmaceutical company. The company specializes in the production of fat-soluble vitamins, retinoids, quinolone antibiotics, and anti-drug-resistant antibiotics. Its leading products include synthetic vitamin E, natural vitamin E, β-carotene, cantharidin, vancomycin hydrochloride, and teicoplanin. The company's preparations, such as injectable levofloxacin lactate, injectable vancomycin hydrochloride, and injectable teicoplanin, occupy important positions in the Chinese market. The company focuses on innovation, competitive development, and talent, investing heavily in R&D and maintaining strong international competitiveness.